Durvalumab PlusTremelimumab Combo为不可切除的HCC带来操作系统改进 不可切除的肝细胞癌患者在使用durvalumab(Imfinzi)和tremelimumab进行一线治疗后获得了总体生存获益。 根据将在2022年胃肠道癌症研讨会上发表的3期HIMALAYA试验(NCT03298451)的结果,与索拉非尼(Nexavar)相比,由durvalumab(Imfinzi)和tremelimumab组成的一线联合...
近日,durvalumab(度伐利尤单抗,Imfinzi)和tremelimumab(Imjudo)的双免疫联合疗法获欧盟批准用于晚期或不可切除肝细胞癌(HCC)肝癌的一线治疗,或者联合铂类化疗用于一线治疗转移性非小细胞肺癌(NSCLC)[1]。 此次度伐利尤单抗联合tremelimumab获批一线...
临床专家分析认为,因为剂量毒性,仅仅采用了一剂CTLA-4单抗Tremelimumab的大剂量冲击使用,但考虑到Tremelimumab的加入较单独的Durvalumab的PFS和OS均有改善,尽管疗效优势没有明显拉开,但仍提示Tremelimumab对疗效的提升作用。如若能够摆脱Tremelimumab的毒性限制,可以连续组合用药,可能会带来PFS和OS上更多惊喜。 HCC本身因器官功...
当用于不可切除的肝细胞癌 (HCC) 患者的一线治疗时,单次高启动剂量的 tremelimumab 加 durvalumab (Imfinzi) 导致总生存期 (OS) 与索拉非尼 (Nexavar) 相比具有统计学意义和临床意义的改善。既往未接受全身治疗且不符合局部治疗条件,符合 HIMALAYA 3 期试验 (NCT03298451) 的主要终点。1 该方法被称为 STRIDE 方...
近日,durvalumab(度伐利尤单抗,Imfinzi)和tremelimumab(Imjudo)的双免疫联合疗法获欧盟批准用于晚期或不可切除肝细胞癌(HCC)肝癌的一线治疗,或者联合铂类化疗用于一线治疗转移性非小细胞肺癌(NSCLC) [1] 。 HIMALAYA试验 HIMALAYA试验为一项随机、开放标签 、多中心全球Ⅲ期试验,16个国家的181个中心参与。研究招募ECOG...
immunostimulatory treatment.Methods:This is a single-arm, open-label, Phase II, multicenter study designed to evaluate the safety and efficacy of durvalumab and tremelimumab for the treatment of HCC patients who have cirrhosis or portal hypertension and are eligible for listing for a liver transplant...
The clinically meaningful overall survival (OS) benefit observed with durvalumab (Imfinzi) plus tremelimumab (Imjudo) in patients with unresectable hepatocellular carcinoma (HCC) naïve to systemic therapy and who are not eligible for local therapy has been sustained at 4 years, according to upda...
The combination of durvalumab and tremelimumab has been approved for patients with unresectable hepatocellular carcinoma. The combination comes with warnings for immune-related adverse events and infusion reactions.
英国制药巨头阿斯利康公司12月28日宣布,其免疫疗法Imfinzi(durvalumab)和Imjudo(tremelimumab)已在日本获批用于治疗三种癌症类型:晚期肝癌、胆道癌和肺癌。 Imfinzi是一种人源单克隆抗体,可与PD-L1蛋白结合并阻断PD-L1与PD-1和CD80蛋白的相互作用,对抗肿瘤的免疫逃避策略并解除对免疫反应的抑制。
Durvalumab (Imfinzi) plus a single priming dose of tremelimumab (Imjudo; STRIDE) led to continued clinically meaningful overall survival (OS) benefit at 4 years compared with sorafenib (Nexavar) in patients with previously untreated, unresectable hepatocellular carcinoma (HCC) not eligib...